RxDoctor Payments Data

Narissa Whitelaw, DO

Family Medicine · Tucson, AZNPI 1023304250

Payments from drug & device makers

$5,063in general payments, 2019–2025

Across 287 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$763
  • AstraZeneca$754
  • GSK$512
  • Pfizer$498
  • Amgen$430
  • Merck$270
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$5,03399%
  • Education$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,063 in reported general payments places this provider in the 90th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$98,620
Medicare patients
187
Services billed
2,360

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide65$109,442
FarxigaDapagliflozin Propanediol28$30,748
XareltoRivaroxaban19$21,683
EliquisApixaban13$20,622
JardianceEmpagliflozin13$20,460
Soliqua 100-33Insulin Glargine/Lixisenatide12$12,829
SynthroidLevothyroxine Sodium67$6,152
Estradiol55$2,362
Atorvastatin Calcium230$2,162
Rosuvastatin Calcium174$1,907
Montelukast Sodium88$1,514
Omeprazole66$1,422
Pantoprazole Sodium93$1,411
Albuterol Sulfate HfaAlbuterol Sulfate59$1,408
Levothyroxine Sodium145$1,226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$202$109,44265 claims
AstraZenecaFarxiga$754$30,74828 claims
Johnson & JohnsonXarelto$33$21,68319 claims
PfizerEliquis$498$20,62213 claims
Boehringer IngelheimJardiance$111$20,46013 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$48$12,82912 claims
AbbVieSynthroid$763$6,15267 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$34$1,226145 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →